452 related articles for article (PubMed ID: 31044544)
1. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
2. Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells.
Martirosyan A; Leonard S; Shi X; Griffith B; Gannett P; Strobl J
J Pharmacol Exp Ther; 2006 May; 317(2):546-52. PubMed ID: 16497787
[TBL] [Abstract][Full Text] [Related]
3. A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis.
Zhang J; Gao X; Wei M; Li Y; Yang G; Yang C; Yu L
Clin Sci (Lond); 2021 Jul; 135(14):1751-1765. PubMed ID: 34282832
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.
Fiskus W; Sharma S; Saha S; Shah B; Devaraj SG; Sun B; Horrigan S; Leveque C; Zu Y; Iyer S; Bhalla KN
Leukemia; 2015 Jun; 29(6):1267-78. PubMed ID: 25482131
[TBL] [Abstract][Full Text] [Related]
6. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
Xavier AC; Ge Y; Taub JW
J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
Xu X; Xie C; Edwards H; Zhou H; Buck SA; Ge Y
PLoS One; 2011 Feb; 6(2):e17138. PubMed ID: 21359182
[TBL] [Abstract][Full Text] [Related]
8. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
9. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
10. The landscape of somatic mutations in Down syndrome-related myeloid disorders.
Yoshida K; Toki T; Okuno Y; Kanezaki R; Shiraishi Y; Sato-Otsubo A; Sanada M; Park MJ; Terui K; Suzuki H; Kon A; Nagata Y; Sato Y; Wang R; Shiba N; Chiba K; Tanaka H; Hama A; Muramatsu H; Hasegawa D; Nakamura K; Kanegane H; Tsukamoto K; Adachi S; Kawakami K; Kato K; Nishimura R; Izraeli S; Hayashi Y; Miyano S; Kojima S; Ito E; Ogawa S
Nat Genet; 2013 Nov; 45(11):1293-9. PubMed ID: 24056718
[TBL] [Abstract][Full Text] [Related]
11. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
[TBL] [Abstract][Full Text] [Related]
12. Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene.
Masetti R; Bertuccio SN; Astolfi A; Chiarini F; Lonetti A; Indio V; De Luca M; Bandini J; Serravalle S; Franzoni M; Pigazzi M; Martelli AM; Basso G; Locatelli F; Pession A
J Hematol Oncol; 2017 Jan; 10(1):26. PubMed ID: 28109323
[TBL] [Abstract][Full Text] [Related]
13. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.
Boztug H; Schumich A; Pötschger U; Mühlegger N; Kolenova A; Reinhardt K; Dworzak M
Cytometry B Clin Cytom; 2013; 84(6):370-8. PubMed ID: 23450818
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia-related malignancies.
Lalonde E; Rentas S; Wertheim G; Cao K; Surrey LF; Lin F; Zhao X; Obstfeld A; Aplenc R; Luo M; Li MM
Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832921
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-155-5p Plays a Critical Role in Transient Leukemia of Down Syndrome by Targeting Tumor Necrosis Factor Receptor Superfamily Members.
Sas V; Pasca S; Jurj A; Pop L; Muramatsu H; Ono H; Dima D; Teodorescu P; Iluta S; Turcas C; Onaciu A; Munteanu R; Zimta AA; Blag C; Popa G; von Gamm EDA; Arghirescu S; Serban M; Man S; Marian M; Petrushev B; Berce C; Colita A; Zdrenghea M; Kojima S; Gulei D; Takahashi Y; Tomuleasa C
Cell Physiol Biochem; 2020 Oct; 54(5):994-1012. PubMed ID: 33006449
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Langebrake C; Creutzig U; Reinhardt D
Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome.
Hara Y; Shiba N; Ohki K; Tabuchi K; Yamato G; Park MJ; Tomizawa D; Kinoshita A; Shimada A; Arakawa H; Saito AM; Kiyokawa N; Tawa A; Horibe K; Taga T; Adachi S; Taki T; Hayashi Y
Genes Chromosomes Cancer; 2017 May; 56(5):394-404. PubMed ID: 28063190
[TBL] [Abstract][Full Text] [Related]
18. Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype.
Wang L; Peters JM; Fuda F; Li L; Karandikar NJ; Koduru P; Wang HY; Chen W
Cytometry B Clin Cytom; 2015; 88(4):244-52. PubMed ID: 25361478
[TBL] [Abstract][Full Text] [Related]
19. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes.
de Rooij JD; Branstetter C; Ma J; Li Y; Walsh MP; Cheng J; Obulkasim A; Dang J; Easton J; Verboon LJ; Mulder HL; Zimmermann M; Koss C; Gupta P; Edmonson M; Rusch M; Lim JY; Reinhardt K; Pigazzi M; Song G; Yeoh AE; Shih LY; Liang DC; Halene S; Krause DS; Zhang J; Downing JR; Locatelli F; Reinhardt D; van den Heuvel-Eibrink MM; Zwaan CM; Fornerod M; Gruber TA
Nat Genet; 2017 Mar; 49(3):451-456. PubMed ID: 28112737
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome for Down syndrome patients with hematopoietic disorders.
Li MJ; Lee NC; Yang YL; Yen HJ; Chang HH; Chien YH; Lu MY; Jou ST; Lin KH; Hwu WL; Lin DT
J Formos Med Assoc; 2016 Feb; 115(2):94-9. PubMed ID: 26234152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
